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ABSTRACT Many genes are hypothesized to be involved in determining an 
individual's risk for coronary artery disease (CAD). Recent efforts have focused on 
the genetic architecture of quantitative traits related to risk for CAD. Studies 
relating genetic variation in the structural gene for apolipoprotein E to plasma 
levels of apolipoprotein E illustrate strategies to  begin to understand the genetic 
architecture of plasma levels of apolipoprotein E. Studies using a measured gene 
approach suggest that variability in the isoforms of apolipoprotein E explain some, 
but not all, of the variability in plasma levels of apolipoprotein E. Products of other 
genes may be associated with plasma apolipoprotein E variability. No studies to 
date have presented findings from an unmeasured gene approach to plasma levels 
of apolipoprotein E. Models most often used in the unmeasured gene approach are 
not appropriate for studies of plasma levels of apolipoprotein E and perhaps are 
inappropriate for the study of other traits. Variations of the models are suggested 
to ask if a single unmeasured gene is the same gene defined by the apolipoprotein 
E isoforms. Another model can be used t o  ask if there is evidence for genes 
influencing levels of apolipoprotein E after accounting for the effects of the iso- 
forms. Both the measured gene and unmeasured gene strategies have limitations. 
The failure of most models to allow for the complexity of genotype-phenotype 
relationships or the heterogeneity of genetic causes will slow the progress to  
understand the genetic architecture of quantitative traits associated with risk for 
CAD. c I 993 WiIey-Liss, Inc 
In the United States, coronary artery dis- 
ease (CAD) is the single largest cause of 
death, accounting for 24% of all deaths 
(American Heart Association, 1991). CAD 
represents the clinical manifestations of cor- 
onary atherosclerosis. CAD begins in child- 
hood with the accumulation of lipid in the 
intima of arteries t o  form fatty streaks 
(McGill, 1988). At some sites in the coronary 
arteries, the fatty streaks thicken by the 
continued accumulation of abnormal lipid, 
of smooth muscle cells, and of connective tis- 
sue to form fibrous plaques. In young adult- 
hood, fibrous plaques increase in extent and 
thickess and undergo calcification and vas- 
cularization. In middle years and later, 
qualitative changes in the fibrous plaque 
may result in hemorrhage, ulceration, and 
thrombosis, potentially causing arterial oc- 
clusion and catastrophic ischemic necrosis 
of vital organs (McGill, 1988). In the general 
population, clinical disease is manifested 
typically in the fifth and sixth decades as  
angina pectoris or as  sudden plaque rupture 
with thrombosis, vessel occlusion, and myo- 
cardial infarction with or without sudden 
death. Approximately 800,000 myocardial 
infarctions occur yearly in the United 
States, and more than 500,000 deaths and 2 
million hospitalizations annually are associ- 
ated with CAI) (Higgins and Thom, 1989). 
The major risk factors for CAD include 
older age, male gender, smoking, family his- 
tory of premature disease, hypertension, di- 
abetes, obesity, and abnormal levels of' lipids 
(cholesterol and trjglyceride) and lipopro- 
teins (low-density lipoprotein cholesterol 
[LDL-C] and high-density lipoprotein cho- 
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lesterol IHDL-CI). Other risk factors have 
been identified including fat patterning, 
physical inactivity, dietary excesses or defi- 
ciencies, and a stressful lifestyle. Case-con- 
trol studies, twin studies, and family studies 
have provided evidence that CAD aggre- 
gates in families (Berg, 1983; Reed et al., 
1986; Nora et al., 1991). However, in most 
families, CAD does not segregate as  if deter- 
mined by a single Mendelian gene. This is 
not unexpected when the risk of developing 
disease is determined by the levels of many 
intermediate quantitative traits whose dis- 
tributions are each influenced by the segre- 
gation of many genes and environmental 
factors (Sing and Moll, 1990a). 
Several studies have presented evidence 
that genetic differences among individuals 
can explain at  least 40% of the variability in 
LDL-C and 30% of the variability in HDL-C 
(Sing et al., 1988). These studies provide es- 
timates of the contribution from all of the 
genes together to variability in a quantita- 
tive trait under the assumptions that the 
contributions from the genes are all equal, 
small, and additive. There are also rare mu- 
tations that can explain Mendelian segrega- 
tion of very high LDL-C levels and very low 
HDL-C levels in some families (Sing et al., 
1988). Since only a small proportion of fami- 
lies have these rare mutations, they can only 
explain a small proportion of the genetic 
variability in these traits and CAD in the 
population at large. 
G ENETlC ARCHITECTURE 
Many genes are hypothesized to be in- 
volved in determining an individual’s risk 
for CAD (Sing and Moll, 1990a). Specific risk 
factors, like measures of lipid metabolism, 
are associated with variation in several 
genes (Sing and Boerwinkle, 1987; Kaprio et 
al., 1991; Kessling et al., 1991). As a conse- 
quence of contributions from many genes 
and the pleiotropic effect of individual 
genes, recent efforts have focused on genetic 
architecture of quantitative traits related to 
risk for CAD (Sing and Davignon, 1985; 
Boerwinkle and Sing, 1987; Sing and Boer- 
winkle, 1987; Kaprio et al., 1991; Boerwin- 
kle, 1992). The genetic architecture of a trait 
in a particular population is defined by the 
number of genes involved in the phenotypic 
expression of the trait, the number of alleles 
of each gene and their relative frequencies, 
the impact of each allele on the level and 
variability of the trait, and the impact of 
each allele on the relationship between the 
trait and other risk factors for the disease of 
interest (Sing and Moll, 1990b). 
Expectations about the relative frequen- 
cies of alleles and the size of their effects on 
CAD risk have come from many studies 
(Sing and Moll, 1990a,b). These include 
studies of the gene coding for the LDL recep- 
tor and the defects in it which are associated 
with familial hypercholesterolemia (Brown 
and Goldstein, 1986), the gene coding for 
apolipoprotein E and the protein isoforms 
(Davignon et al., 19881, and the genes and 
restriction fragment length polymorphism 
(RFLP) markers in them coding for other 
proteins hypothesized to be involved in reg- 
ulation of lipid metabolism (Humphries, 
1988; Kessling et al., 1991). It is expected 
that there will be a few mutations or alleles 
that will be rare but have large effects on 
risk factors for CAD; yet, they will have 
small effects on the risk of CAD. It is ex- 
pected that most of the genetic effects on 
CAD risk will probably come from common 
allelic variation for many genes with small 
effects. As the number of genes involved in 
the genetic architecture increases, the num- 
ber of families segregating for the same 
genes is expected to decrease (Sing and Moll, 
1990bl. Studies t o  understand the genetic 
architecture of CAD and its risk factors have 
begun. Among quantitative risk factors for 
CAD, plasma lipoprotein (a) is an  example of 
a trait with more than 90% of the genetic 
variation identified (Boerwinkle, 1992; 
Boerwinkle et al., 1992). In contrast to what 
is known about the genetic architecture of 
plasma lipoprotein (a), less is known about 
the genetic architecture of other risk factors 
and little is known about the genetic archi- 
tecture of CAD at this time. 
APOLl POPROTEI NS 
To begin t o  understand the genetic archi- 
tecture of CAD and its risk factors, many 
studies have focused on measures of lipid 
metabolism. The two major lipids, choles- 
terol and triglyceride, are insoluble and cir- 
culate between the gut, liver, and peripheral 
tissues as lipoprotein particles. It is hypoth- 
esized that many genes are involved in the 
regulation of lipid uptake in the gut, metab- 
olism in the plasma, liver, and peripheral 
cells and removal from the body. One way to 
look for genetic influence is to study the pro- 
tein components of these lipoproteins since 
the proteins are encoded by genes. Apoli- 
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poproteins, protein constituents of lipopro- 
teins, have various structural and metabolic 
roles related t o  the metabolism of lipids. Al- 
though all of the apolipoproteins have im- 
portant structural roles in the transport of 
lipids, most have specialized functions. 
Chan et al. (1990) review the structure and 
function of specific apolipoproteins, while 
Ferrell (1992) reviews many of the known 
associations between polymorphic variation 
in apolipoprotein genes and quantitative 
variation in lipid and lipoprotein levels. 
Assays have been developed to measure 
the quantitative plasma levels of many apo- 
lipoproteins (Kottke et al., 1991). Since the 
chromosomal location of many of the struc- 
tural genes for apolipoproteins is known 
(Chan et al., 1990), variation in these genes 
can be related to variation in plasma levels 
of apolipoproteins. There are many studies 
relating genetic variation in the structural 
gene for apolipoprotein E to plasma levels of 
apolipoprotein E (Boerwinkle and Uter- 
mann, 1988; Havekes et al., 1988; Hanis et 
al., 1991; Kaprio et al., 1991; Reilly et al., 
1991). These studies, as well as several in 
progress, illustrate some of the strategies 
being implemented t o  begin to understand 
the genetic architecture of plasma levels of 
apolipoprotein E. 
APOLIPOPROTEIN E 
Apolipoprotein E is synthesized in various 
organs including the liver, brain, spleen, 
and kidney, and is present in high concen- 
trations in interstitial fluid, where it ap- 
pears to participate in cholesterol redistri- 
bution from cells with excess cholesterol to 
those requiring cholesterol (Mahley, 1988). 
The three major isoforms of apolipoprotein 
E, referred to as apo E2, apo E3 and apo E4, 
are the products of three alleles ( € 2 ,  €3, €4) of 
a single gene on chromosome 19. The iso- 
forms can be determined by isoelectric focus- 
ing (Kamboh et al., 1988). Apo E3 differs 
from apo E2 and apo E4 by one amino acid 
difference a t  either residue 112 or 158. 
Functional differences have been identified 
among the isoforms. Apo E2 has impaired 
receptor binding activity compared to apo 
E3, while apo E4 has enhanced in vivo ca- 
tabolism (Mahley, 1988). 
One assumption that is made in studies 
using the isoforms is that individuals with 
the same isoform phenotypes have the same 
genotypes. In a direct comparison of apo E 
isoforms measured by isolectric focusing 
(Kamboh et al., 1988) and apo E genotypes a t  
the two common polymorphic sites (amino 
acids 112 and 158), there was only one dis- 
cordant allele in a sample of 195 unrelated 
heterozygoes from a population-based sam- 
ple (Mailly et al., 1992). This finding sug- 
gests that apo E isoforms can be used to 
infer apo E genotypes. 
Different apo E isoforms are associated 
with different risks of atherosclerosis. Two 
recent cross-sectional studies have shown 
this association. The Pathobiological Deter- 
minants of Atherosclerosis in Youth (PDAY) 
study by Hixson et al. (1991) considered le- 
sions in autopsied young males, while the 
other study considered angiographically 
defined disease in a sample of adult males 
(Nieminen et al., 1992). In both studies, in- 
dividuals who were homozygotes or het- 
erozygotes for apo E4 had higher prevalence 
of disease. In a nested case-control study of 
partipants in the Multiple Risk Factor Inter- 
vention Trial, the presence of apo E4 was 
associated with an  increased risk of disease 
that was most evident for fatal cases (Eich- 
ner et al., 1993). 
TWO STRATEGIES FOR STUDYING THE 
RELATIONSHIP BETWEEN GENES AND 
PLASMA LEVELS OF APOLIPOPROTEINS 
There are two strategies that have been 
used to  study the relationship between 
genes and quantitative traits like apolipo- 
proteins (Boerwinkle et al., 1987; Sing and 
Boerwinkle, 1987). The first strategy has 
been called a bottom-up, measured gene ap- 
proach. It involves obtaining measures of 
genes and of quantitative trait levels in an 
unrelated sample and then estimating the 
effects of genes on the trait of interest. Ex- 
amples of this approach investigating the 
association of apo E isoforms with levels of 
plasma apolipoprotein E are given in the 
studies by Boerwinkle and Utermann 
(1988), Kaprio et al. (1991), Hanis et al. 
(19911, and Reilly et al. (1991). Some of 
these studies are discussed in detail later. 
The second strategy has been called atop- 
down, unmeasured gene approach. I t  in- 
cludes obtaining measures of a quantitative 
trait in a sample of pedigrees and then ap- 
plying statistical techniques (i.e., complex 
segregation analysis [Elston and Stewart, 
1971; Lalouel et al., 19831) to  search for evi- 
dence that unmeasured genes are associated 
with variation in the quantitative trait. 
These unmeasured genes can include 
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polygenes and/or an unmeasured single 
gene with a large impact on the level of a 
quantitative trait. Examples of unmeasured 
gene approaches in studies of quantitative 
levels of apolipoproteins in pedigrees are 
given by Hasstedt et al. (19871, Pairitz et al. 
(19881, and Moll et al. (1989). If there is sta- 
tistical evidence that an unmeasured single 
gene has a large impact on the trait, then 
specific pedigrees that are most likely t o  be 
segregating for this unmeasured single gene 
can be identified. These pedigrees would 
then be used in future molecular studies. An 
unmeasured gene approach can be useful 
when there are no candidate genes or candi- 
date genes cannot be measured. Such an ap- 
proach can also be useful to provide evidence 
for new genes even if some genes have al- 
ready been identified and measured. Alter- 
natively, an  unmeasured gene approach can 
provide an estimate of the total genetic con- 
tribution to the variation in a trait. No stud- 
ies, to date, have presented an  application of 
a top-down, unmeasured gene approach t o  
plasma levels of apolipoprotein E. 
PLASMA APOLIPOPROTEIN E: MEASURED 
GENE APPROACH 
The impact of the common alleles at the 
structural gene coding for apo E on plasma 
apolipoprotein E has been estimated in 453 
unrelated Caucasians 26-63 years of age in 
a population-based sample (Kaprio et al., 
1991). The relative frequencies of the three 
alleles that code for the apo E isoforms in 
this sample (apo €2 = 0.073, ~3 = 0.777, and 
€4 = 0.150) are similar to those reported for 
other Caucasian populations in North 
America (Davignon et al., 1988; Gerdes et 
al., 1992). The distribution of genotypes is 
not different between males and females 
and the pooled frequencies are in Hardy- 
Weinberg equilibrium. In the 227 men in 
this sample, plasma levels of apolipoprotein 
E ranged from 1.540.7 mg/dl with a mean 
of 5.5 mg/dl. In the 226 women, the levels 
ranged from 1.3-13.4 mg/dl with a mean of 
5.2 mg/dl. In the men, 4.5% of the sample 
variability was explained by linear regres- 
sion of plasma levels of apolipoprotein E on 
date of assay, age, age squared, height, 
weight, and smoking status. In women, 
these same concomitants explained 6.3% of 
the sample variability. After adjustment for 
concomitants, Kaprio et al. (1991) estimated 
the contribution of apo E isoforms to the 
population variance of apolipoprotein E was 
11.6% in males and 16.8% in females. This 
contribution was estimated using the unbi- 
ased statistic given by Boerwinkle and Sing 
(1986). 
A measured gene approach has been ap- 
plied to plasma apolipoprotein E in two 
other studies. Hanis et al. (1991) estimated 
the contribution of apo E isoforms t o  plasma 
apolipoprotein E variability at 0.9% in 
males, 3.9% in postmenopausal females, 
and 27.5% in premenopausal females sam- 
pled from Starr County, Texas. Boerwinkle 
and Utermann (1988) estimated the contri- 
bution t o  be 20.2% in a sample of male and 
female blood bank donors from Marburg and 
Geissen. The findings from these studies 
suggest that differences in apo E isoforms 
are associated with differences in plasma 
apolipoprotein E levels. However, the asso- 
ciation varies by population, gender, and 
menopausal status. These two studies differ 
from one another and from the study of un- 
related adults by Kaprio et al. (1991) in the 
age range of the participants, the specific 
concomitants considered as well as the 
methods used to adjust plasma levels of 
apolipoprotein E for concomitants, the sta- 
tistical methods used to estimate the con- 
tribution of isoform variability to plasma 
apolipoprotein E variability, the frequencies 
of the isoforms, and the frequencies of other 
genes and environmental exposures. These 
three studies together support the inference 
that variability in the isoforms does not ex- 
plain all of the variability in plasma levels of 
apolipoprotein E and that the contribution 
from apo E isoforms to plasma levels of apo- 
lipoprotein E varies within and between 
populations (Boerwinkle and Utermann, 
1988; Hanis et al., 1991; Kaprio et al.. 1991). 
These studies also suggest that, although 
variation in the apo E isoforms explains 
some of the plasma apolipoprotein E vari- 
ability, the products of other genes or other 
genes themselves may also be associated 
with apolipoprotein E variability. 
PLASMA APOLIPOPROTEIN E: 
UNMEASURED GENE APPROACH 
No studies to date have presented the 
findings from an unmeasured gene ap- 
proach to plasma levels of apolipoprotein E. 
Any unmeasured gene study would need to 
consider the findings from the measured 
gene studies when selecting the models t o  be 
fit to  the family data. The models that have 
been applied most often for quantitative 
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traits would not be appropriate for plasma 
levels of apolipoprotein E and would need to 
be extended. The models most often used 
have been described in detail elsewhere 
(Moll et al., 1989, 1991; MacCluer, 1992). 
Briefly, these models assume that the ob- 
served distribution of a quantitative trait is 
a consequence of the independent contribu- 
tions from the following: a single genetic or 
nontransmitted environmental factor with a 
large effect on the level of the quantitative 
trait, the effects of a large number of inde- 
pendent polygenes each with a small, ad- 
ditive effect, the effects of shared envi- 
ronments (often defined by household 
membership), and individual-specific envi- 
ronmental influences. The major factor is 
modeled as having two alternatives (L for 
lower and H for higher) that may be of either 
genetic or nontransmitted environmental 
origin. These combine to define three dis- 
tinct groups or classes (also referred to as 
ousiotypes [Cannings et al., 19781) of indi- 
viduals, denoted LL, LH, and HH. The rela- 
tive frequency of L is denoted p and the rela- 
tive frequency of H is equal t o  1-p. Most 
applications of the unmeasured gene ap- 
proach assume that there is Hardy-Wein- 
berg equilibrium in the population being 
sampled and so the relative frequency of LL, 
LH, and HH individuals is p2, 2pq, and q2, 
respectively. Other parameters of the model 
include a phenotypic mean for each ousio- 
type (LL, LH, and HH) and a phenotypic 
variance among individuals with the same 
ousiotype. It is assumed that this variance is 
the same for all three ousiotypes. Based on 
the findings from studies using the mea- 
sured gene approach, this assumption may 
not be valid (Reilly et al., 1991). The model 
partitions this variance into a fraction at- 
tributable to polygenes, a fraction attribut- 
able to shared environmental effects, and a 
fraction that is attributable to individual- 
specific environmental effects and measure- 
ment error. T ~ ,  T ~ ,  and T~ are the probabili- 
ties that individuals of ousiotypes LL, LH, 
and HH, respectively, transmit the L factor 
to their offspring. These transmission prob- 
abilities define alternative models. For the 
general transmission model (Lalouel et al., 
19831, these transmission probabilities are 
each estimated under the constraint that 
they be inclusive 0-1. A single gene Mende- 
lian model defines these probabilities of 
transmitting alleles from parents to off- 
spring as being -rl = 1.0, T~ = 0.5, and 
T~ = 0.0. The nontransmitted environmen- 
tal factor model predicts that the probablity 
that a n  individual is one ousiotype or an- 
other is independent of his or her generation 
and independent of the ousiotypes of his or 
her parents (Elston and Stewart, 1971). Un- 
der this model, each transmission probabil- 
ity is taken to be equal to  p, the relative 
frequency of L. 
Testing hypotheses about parameters cor- 
responds to  restricting one or  more parame- 
ters to specific hypothesized values, while 
estimating the remaining parameters from 
the data. The model in which all three trans- 
mission probabilities are estimated is con- 
sidered the unrestricted model and is often 
called the general transmission model. The 
restricted models include a model with the 
transmission probabilities constrained to be 
equal to Mendelian expectation (a single 
gene model) or a model in which the trans- 
mission probabilities are all equal to the rel- 
ative frequency of L (a nontransmitted envi- 
ronmental model). 
For the unrestricted and restricted mod- 
els, a likelihood is computed that is a func- 
tion of the observed data and the parame- 
ters of the model. These likelihoods are a 
posteriori probabilities after the data have 
been observed. Twice the difference between 
the maximum of the log, likelihood of the 
model with unrestricted parameters and the 
maximum of the log, likelihood of a model 
with restricted parameters is distributed 
approximately as  a chi-square when the null 
hypothesis is true. The degrees of freedom 
for this chi-square test are equal to the num- 
ber of parameters restricted to values stated 
by the hypothesis. The likelihoods of the 
models can be computed using the Pedigree 
Analysis Package (PAP) (Hasstedt, 1989). 
The likelihoods for each model considered 
can be maximized using a quasi-Newton 
method (Lalouel, 1979). Several other com- 
puter programs are available to compute ex- 
act likelihoods as  well as  approximations to 
the likelihoods for the models described 
above (MacCluer, 1992). 
The models described above, with or with- 
out the shared environmental effects, have 
been used extensively (see MacCluer, 1992) 
and are currently being used (e.g., Schu- 
macher et al., 1992). However, they are not 
appropriate for plasma apolipoprotein E 
given that six genotypes defined by apo €2, 
apo €3, and apo €4 have been shown in sev- 
eral studies to explain a large proportion of 
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the variability. The models used in the un- 
measured approach would first have to con- 
sider three alternatives for the factor, rather 
than two. A model with three alleles has 
only been used once before in a study of li- 
poprotein (a) (Hasstedt and Williams, 1986). 
A model with three alternatives for the fac- 
tor would have six means. Under the single 
gene model, the transmission probabilities 
would be fixed at their Mendelian expecta- 
tion. However, under the nontransmitted 
environmental factor model, there would be 
two transmission probabilities that would 
need to be estimated and under the unre- 
stricted model there would be 12 transmis- 
sion probabilities that would need to be esti- 
mated. Given the difficulties in estimating 
transmission probabilities, it seems unlikely 
that an unrestricted model with three alter- 
natives for the factor with a large effect on 
the levels of the trait will be applied in the 
near future. While it is possible to fit a sin- 
gle gene model and a nontransmitted envi- 
ronmental model with three alternatives for 
the factor with a large effect, the comparison 
of these models is complicated by the fact 
that neither of these models can be consid- 
ered unrestricted with respect to the other 
model. That is, these two models are not 
nested. The inability to be able to compare 
different models with three alternatives for 
the factor illustrates the limitations in the 
models to allow for the complexity of the 
genotype-phenotype relationships. The po- 
tential for future studies to provide statisti- 
cal evidence for new genes will depend, to 
some extent, on how much the models evolve 
in the next few years. In  addition to limita- 
tions in the models, there are a number of 
known sources of both Type I and Type I1 
errors that could jeopardize the validity of 
findings from a top-down, unmeasured gene 
approach (Moll, 1993). 
Although the models used most often are 
not appropriate and models with three alter- 
natives for the factor introduce estimation 
and hypothesis testing challenges, there is 
one specific model that could be applied to 
plasma levels of apolipoprotein E that would 
address a very specific question. The ques- 
tion that could be addressed is whether a 
single unmeasured gene with three alterna- 
tive factors and a large effect on plasma lev- 
els of apolipoprotein E is the same gene de- 
fined by the gene that codes for the apo E 
isoforms. The model would include the esti- 
mation of relative frequencies of two alleles 
since the relative frequency of the third al- 
lele is the difference between l and the sum 
of the estimates of the relative frequencies of 
the other two alleles. The model would also 
include the estimation of six genotype-spe- 
cific means, a phenotypic variance among 
individuals with the same genotype, a pa- 
rameter that reflects the effects of poly- 
genes, and a parameter that reflects the ef- 
fects of shared environmental factors. The 
most probable genotype could be assigned t o  
each individual in the study and a test of 
independence between the genotype at the 
unmeasured gene and the genotypes that 
code for the apo E isoforms could be made. 
This application of the unmeasured ap- 
proach would provide an assessment of 
whether complex segregation analysis (i.e., 
an  unmeasured gene approach) can identify 
polymorphic genes that are known to affect 
levels of a quantitative trait. 
Simulation studies have suggested that 
the top-down, unmeasured gene approach is 
limited to detecting only those single gene 
effects that are relatively large (MacLean et 
al., 1975; Go et al., 1978; Burns et al., 1984). 
The size of the effects is a function of the 
relative frequency of the alleles, the means 
for the genotypes, and the variance within 
each genotype. In general, simulation stud- 
ies have suggested that the difference be- 
tween the means for different genotypes 
needs to be a t  least one and a half within 
genotype standard deviations apart in order 
to be able to detect the effects of a single 
gene (MacLean et al., 1975; Go et al., 1978; 
Burns et al., 1984). The reported difference 
between means for plasma levels of apo- 
lipoprotein E for the six genotypes defined 
by the apo E isoforms is not each one and a 
half standard deviations in the study by Ha- 
nis et al. (1991). Therefore, it is not clear 
whether the genes that code for the apo E 
isoforms have effects that are large enough 
to be detected with the top-down, unmea- 
sured gene approach. 
A different application of the unmeasured 
approach could address the question of 
whether there is evidence that there are 
genes, in addition to the gene that codes for 
the apo E isoforms, that influence the levels 
of plasma apolipoprotein E. The model to 
address this question would include unmea- 
sured genes as  well as the gene that codes 
for the apo E isoforms. In the model, the 
different isoforms would be associated with 
different levels of plasma apolipoprotein E 
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and the variability among individuals with 
the same isoform would be explained by 
polygenes, shared environments, and resid- 
ual effects. This model was originally devel- 
oped for nuclear families (Boenvinkle et al., 
1986; Boerwinkle and Sing, 1987). 
This model could be extended to allow the 
effects of the gene that codes for the isoforms 
to  be gender specific. Then the unrestricted 
model would include 12 means: six geno- 
type-specific means for males and six geno- 
type-specific means for females. The other 
parameters would include a standard devia- 
tion that is equal for all genotypes and both 
genders as well as parameters for the contri- 
butions of polygenes and shared environ- 
ments t o  the variability among individuals 
with the same genotype and gender. Re- 
stricted models would be associated with hy- 
potheses that the isoforms do not contribute 
to variability andlor the unmeasured poly- 
genes do not contribute to variability andlor 
the shared environments do not contribute 
to variability. Other unrestricted models 
could test the hypothesis that the isoform 
means are equal for males and females. The 
maximum of the log, likelihoods for the un- 
restricted and restricted models could be 
computed using PAP (Hasstedt, 1989). If the 
restricted models that did not include iso- 
forms or did not include polygenes were re- 
jected when compared to the unrestricted 
model, that would be evidence that there are 
genes, in addition to the gene that codes for 
the apo E isoforms, that influence the 
plasma levels of apolipoprotein E. Prelimi- 
nary studies in a population-based sample of 
pedigrees suggest that there is evidence for 
these other, new genes and that the genetic 
architecture of apolipoprotein E will not be 
limited to the gene that codes for the apo E 
isoforms. 
FUTURE STUDIES 
In thinking about the design of future 
studies to identify these new genes, one ap- 
proach would be to limit measured o r  un- 
measured studies to pedigrees in which all 
individuals are homozygotes for apo €3. Apo 
€3  has the highest relative frequency in ev- 
ery population studied so far (Gerdes et al., 
1992). Based on the relative frequencies re- 
ported by Kaprio et al. (19911, it is expected 
that 60.4% of the individuals from the popu- 
lation sampled by that study would be ho- 
mozygotes for apo ~ 3 .  Making assumptions, 
36.4% of all matings would be between two 
homozygotes for apo €3. If one were sam- 
pling three generation pedigrees, then ap- 
proximately 13.2% of all these pedigrees 
would have four grandparents who were ho- 
mozygotes for apo €3. While a higher fre- 
quency of nuclear families would have all 
homozygotes for €3 compared to three gener- 
ation pedigrees, the three generation pedi- 
grees would most likely provide more power 
to detect segregation (Burns et al., 1984). 
Restricting either measured gene or unmea- 
sured gene approaches to the nuclear fami- 
lies or pedigrees in which all individuals are 
homozygotes for apo €3 would control for the 
isoform variability. If the unmeasured ap- 
proach provided evidence for a single gene 
with a large effect on plasma levels of apo- 
lipoprotein E, then specific pedigrees could 
be identified, in which all the individuals 
are €33 homozygotes, that are the most 
likely to be segregating for the unmeasured 
single gene with a large effect. These pedi- 
grees could be the focus of future molecular 
studies. Alternatively, sibling pairs in all 
the pedigrees in which all individuals are 
€33 homozygotes could be used t o  detect 
linkage between a measured gene and quan- 
titative levels of apolipoprotein E (Haseman 
and Elston, 1972; Amos et al., 1989). This 
model-free approach has been used for 
quantitative levels of lipoprotein(a1 (Boer- 
winkle et al., 1992). 
CONCLUSIONS 
The gcnetic architecture of plasma apo- 
lipoprotein E is just beginning to emerge 
and will most probably not be simple. Apo E 
isoforms do explain some of the variability 
in plasma levels of apolipoprotein E. I t  is 
very likely that there are genes other than 
the gene that codes for the apo E isoforms 
that also influence plasma apolipoprotein 
levels. The challenge will be to identify these 
other genes. 
The measured and unmeasured gene ap- 
proaches provide evidence that genes do 
pIay a role in the variability of the levels of 
many quantitative traits thought to be im- 
portant for CAD. However, any inferences 
from either the measured or unmeasured 
approach will have to be interpreted with 
caution for any quantitative trait. The im- 
pact of variation in any specific gene will 
depend on a number of host characteristics 
such as other genes, age, gender, concomi- 
tant diseases, and environmental exposures 
(Sing et al., 1992). There are many examples 
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in the literature that suggest that gene-gene 
interaction as well as gene-environment in- 
teraction may not be rare phenomena (Ne- 
et al-, 1987; Reilly et al., 1992; Sing et 
al., 1992). While stratification might be a 
good approach for certain situations to con- 
trol for gene-gene interactions (i.e., consid- 
eration Of Only pedigrees with E33 homozy- 
gotes), it is clear that stratification will not 
be appropriate as a method t o  control for 
many genes simu~taneous~y or to control for 
many concomitants. 
Almost all ofthe models used so far in the 
measured and unmeasured amroaches are 
Boeminkle E, Leffert CC, Lin J, Lackner C, Chiesa G, 
Hobbs HH (1992) Apolipoprotein (a) gene accounts for 
greater than 90% of the variation in plasma lipopro- 
tein (a) concentrations. J. Clin. Invest. 90.5240. 
Boerwinkle E. Sing CF (1986) Bias of the contribution of 
single-locus effects t o  the variance of a quantitative 
trait. Am. J. Hum. Genet. 39:137-144. 
Boerwinkle E, Sing CF (1987) The use ofmeasured gen- 
otype information of quantitative phenotypes in man 
111. Simultaneous estimates of the frequencies and 
effects of the apolipoprotein E polymorphism and re- 
sidual polygenic effects on cholesterol, betalipoprotein 
and triglyceride levels. Ann. Hum. Genet. 51,211-226. 
Boerwinkle E, Utermann G 11988) Siniultaneous effects 
of the apolipoprotein E polymorphism on apolipopro- 
tein E, apolipoprotein B, and cholesterol metabolism. 
Am. J. Hum. Genet. 42t104-112. 
naive representations and faif to allow for 
complexity of genotype-phenotype relation- 
ships or the heterogeneity of genetic causes 
among individuals and pedigrees that make 
up the population at large (Sing and Reilly, 
1993). Recently, there have been applica- 
tions using both the measured and unmea- 
sured approach that have begun to incorpo- 
rate genetic interactions with concomitants 
like age and gender (Perusse et al., 1991; 
Rebbeck et al., 1991; Reilly et al., 1991, 
1992, 1993). Failure to incorporate these 
concomitants will slow the progress to un- 
derstand the genetic architecture of quanti- 
tative traits associated with the develop- 
ment and progression of atherosclerosis. 
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